These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15585972)

  • 21. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
    Tagami T; Ernsting MJ; Li SD
    J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
    Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
    J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lyophilisomes: Potential carriers for tumor targeting.
    van Bracht E; Geutjes PJ; Woestenenk R; Wismans RG; Oosterwijk E; van Kuppevelt TH; Daamen WF
    J Control Release; 2010 Nov; 148(1):e7-8. PubMed ID: 21529636
    [No Abstract]   [Full Text] [Related]  

  • 24. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligonucleotide delivery to tumours using macromolecular carriers.
    Dass CR
    Biotechnol Appl Biochem; 2004 Oct; 40(Pt 2):113-22. PubMed ID: 15070400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of sol-gel mesoporous silica materials providing a slow release of doxorubicin.
    Prokopowicz M; Przyjazny A
    J Microencapsul; 2007 Nov; 24(7):682-701. PubMed ID: 17763062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug delivery system of anticancer agent entrapped in temperature-sensitive liposomes combined with local hyperthermia].
    Takahashi T; Kumai K; Ishibiki K; Abe O; Tadakuma T; Yasuda T; Tomita T
    Nihon Rinsho; 1989 Jun; 47(6):1408-11. PubMed ID: 2770001
    [No Abstract]   [Full Text] [Related]  

  • 28. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes.
    Arai T; Benny O; Joki T; Menon LG; Machluf M; Abe T; Carroll RS; Black PM
    Anticancer Res; 2010 Apr; 30(4):1057-64. PubMed ID: 20530409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxil receives FDA market clearance.
    AIDS Patient Care STDS; 1996 Apr; 10(2):135. PubMed ID: 11361702
    [No Abstract]   [Full Text] [Related]  

  • 31. Complete remission of a case of classical Kaposi's sarcoma with liposomal doxorubicin and radiotherapy.
    Ezquerra GM; Redonnet MS; Cuchillero RO; Millet PU
    J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):901-2. PubMed ID: 16898935
    [No Abstract]   [Full Text] [Related]  

  • 32. Reverse micelle-loaded lipid nanocarriers: a novel drug delivery system for the sustained release of doxorubicin hydrochloride.
    Vrignaud S; Anton N; Gayet P; Benoit JP; Saulnier P
    Eur J Pharm Biopharm; 2011 Sep; 79(1):197-204. PubMed ID: 21345371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.
    Tacar O; Sriamornsak P; Dass CR
    J Pharm Pharmacol; 2013 Feb; 65(2):157-70. PubMed ID: 23278683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor cell killing efficiency of doxorubicin loaded microbubbles after ultrasound exposure.
    Lentacker I; Geers B; Demeester J; De Smedt SC; Sanders NN
    J Control Release; 2010 Nov; 148(1):e113-4. PubMed ID: 21529584
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent advances in the field of nanometric drug carriers.
    Ogier J; Arnauld T; Doris E
    Future Med Chem; 2009 Jul; 1(4):693-711. PubMed ID: 21426033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new ligand for targeted drug delivery to tumor stromal cells.
    Park K
    J Control Release; 2010 Jul; 145(2):75. PubMed ID: 20576503
    [No Abstract]   [Full Text] [Related]  

  • 38. Self-assembled liposome-loaded microbubbles: The missing link for safe and efficient ultrasound triggered drug-delivery.
    Geers B; Lentacker I; Sanders NN; Demeester J; Meairs S; De Smedt SC
    J Control Release; 2011 Jun; 152(2):249-56. PubMed ID: 21362448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
    Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
    J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.